Gynuity
DocumentsDate added
<p>Gynuity and colleagues compiled a series of Frequently Asked Questions (<span>FAQ</span>s) and their answers aimed at giving medical abortion providers and women’s health advocates the language to discuss the occurrence of severe infections caused by Clostridium sordellii following mifepristone-misoprostol medical abortion so they are able to present the science in an informed and responsible manner.</p>
<p> </p>
This resource is also available in Spanish and Turkish and can be downloaded by following this http://gynuity.org/resources/info/faqs-on-fatal-infection-and-medical-abortion-technical-version/ ">link.
Homepage: http://gynuity.org/resources/
Blood Loss After Vaginal Delivery: What Do Objective Measurements Tell Us About Postpartum Hemorrhaghot!
11/30/2009
Hits: 270
This research summary reports on data collected through a series of large-scale trials conducted by Gynuity and colleagues to evaluate the effectiveness of misoprostol for postpartum hemorrhage. As part of this study, blood loss after vaginal delivery was collected and measured systematically for over 39,000 deliveries. The summary describes the objective measurement techniques used and key outcomes.
Homepage: http://gynuity.org/resources/
This annotated bibliography provides basic information about the studies that were used to create the regimen outlined in the brochure Instructions for Use: Abortion Induction with Misoprostol in Pregnancies up to 9 Weeks LMP.
Homepage: http://gynuity.org/resources/
Misoprostol for the Prevention of Postpartum Hemorrhage: Findings from Clinical Research Trial in Chhot!
11/30/2009
Hits: 247
This research summary describes the results of a study on the use of misoprostol for the prevention of postpartum hemorrhage conducted in Pakistan.
Homepage: http://gynuity.org/resources/
This reference list forms the basis for the regimen outlined in the brochure Instructions for Use (IFU): Misoprostol for Treatment of Incomplete Abortion and Miscarriage.
Homepage: http://gynuity.org/resources/
<div>
<p>This research summary describes the results of a knowledge, attitudes and practices survey on abortion and medical abortion conducted with medical providers and women in three urban areas of Armenia in June and July 2007.</p>
</div>
This research summary describes the results of a knowledge, attitudes and practices survey on abortion and medical abortion conducted with medical providers and women in three urban areas of Armenia in June and July 2007.
Homepage: http://gynuity.org/resources/
Route of Misoprostol Administration: Examining Efficacy, Side Effects and Acceptabilityhot!
11/30/2009
Hits: 239
To date, the large body of high-quality scientific work on misoprostol for women’s health has not systematically addressed the importance of route of administration. Often, the use of misoprostol for women’s health indications follows untested practices with different routes of administration. Clinical research comparing different routes of administration for some indications is relatively scarce. Consequently, assertions about the “best” route of administration for a particular indication are often not grounded in scientific evidence. Moreover, many comparisons do not take into account either the population or provider effect on the efficacy or acceptability of a given route. As a result, experts at a previous meeting entitled “Misoprostol: An emerging technology for women’s health” held at the Population Council in New York in May 2001 identified the need for consensus on the clinical importance of route and an examination of the implications of route for future research and drug development. This report describes the outcomes of a subsequent meeting on this issue organized in 2003..
Homepage: http://gynuity.org/resources/
Gynuity and colleagues compiled a series of Frequently Asked Questions (FAQs) and their answers aimed at giving medical abortion providers and women’s health advocates the language to discuss the occurrence of severe infections caused by Clostridium sordellii following mifepristone-misoprostol medical abortion so they are able to present the science in an informed and responsible manner. This version summarized available information; a technical version is also available.
Homepage: http://gynuity.org/resources/
This summary outlines the potential role of a widely available drug (misoprostol) in reducing deaths from postpartum hemorrhage, and describes an initiative to evaluate misoprostol as an alternative therapy for postpartum hemorrhage prevention and treatment. The document lists the potential advantages of misoprostol (as compared to standard treatments) in resource-constrained settings, describes the rationale, objectives, and protocols related to the research efforts, and outlines a set of related project activities to shape policy and share information in support of misoprostol for postpartum hemorrhage.
Homepage: http://gynuity.org/resources/
Instructions for Use: Abortion Induction with Misoprostol in Pregnancies up to 9 Weeks LMPhot!
11/30/2009
Hits: 229
Gynuity Health Projects and Reproductive Health Technologies Project convened an expert meeting looking at the use of misoprostol for abortion induction. Professionals with epidemiological, clinical and programmatic expertise reached consensus on the appropriate use of misoprostol based on the best current information. The results were compiled in a brochure called “Instructions for Use – (<span>IFU</span>).” The information in this document may serve as a basis for the development of clinical practice guidelines and patient and provider education materials. The brochure will be periodically reviewed and updated with new information and research developments.
Homepage: http://gynuity.org/resources/
<div>
<p>This reference list forms the basis for the regimen outlined in the brochure Instructions for Use (<span>IFU</span>): Abortion Induction with Misoprostol in Pregnancies up to 9 Weeks <span>LMP</span>.</p>
</div>
This reference list forms the basis for the regimen outlined in the brochure Instructions for Use (IFU): Abortion Induction with Misoprostol in Pregnancies up to 9 Weeks LMP.
Homepage: http://gynuity.org/resources/
This issue of Outlook Newsletter, produced by Path with Gynuity Health Projects invited as Guest Editor, focuses on the potential relationship between hormonal contraceptive use and HIV transmission.
Homepage: http://gynuity.org/resources/
<div>
<p>Unsafe abortion is one of the most neglected public health challenges in the Middle East and North Africa (<span>MENA</span>) region, where an estimated one in four pregnancies are unintended—wanting to have a child later or wanting no more children. Many women with unintended pregnancies resort to clandestine abortions that are not safe. This policy brief explores the public health concerns surrounding abortion in <span>MENA</span> and discusses ways to make it both rarer and safer.</p>
</div>
Unsafe abortion is one of the most neglected public health challenges in the Middle East and North Africa (MENA) region, where an estimated one in four pregnancies are unintended—wanting to have a child later or wanting no more children. Many women with unintended pregnancies resort to clandestine abortions that are not safe. This policy brief explores the public health concerns surrounding abortion in MENA and discusses ways to make it both rarer and safer.
Homepage: http://gynuity.org/resources/
As part of our effort to defend mifepristone and medical abortion in the United States, Gynuity and Reproductive Health Technologies Project developed a fact sheet about mifepristone use in the U.S. to provide advocates and policy makers with concise information on regimens, safety and benefits.
Homepage: http://gynuity.org/resources/
Misoprostol for the Treatment of Postpartum Hemorrhage: Findings from Clinical Research Trialshot!
11/30/2009
Hits: 226
This research summary describes the results of a series of clinical trials on the use of misoprostol for the treatment of postpartum hemorrhage.
Homepage: http://gynuity.org/resources/
This project description summarizes a recently completed study conducted in Pakistan to evaluate misoprostol to prevent postpartum hemorrhage.
Homepage: http://gynuity.org/resources/
The meeting summarized in this report was organized in 2001 because up until that point a large body of scientific work supporting the use of misoprostol for a range of reproductive and maternal health indications had not been synthesized in an accessible way. As a result, there had been no consensus on the use of misoprostol for women’s health and no strategic agenda for continuing development of the technology. Meeting participants agreed that a major priority for research and policy is creation of a solid clinical science base for all women’s health problems for which misoprostol is effective. Providers must be trained, guidelines created and women educated so that the use of the drug is safe and effective. Finally, a broader policy strategy is necessary to support program development in identified priority areas.
Homepage: http://gynuity.org/resources/
Expert Meeting Held on Improving Current Therapies and Exploring New Options in Abortifacient Technohot!
11/30/2009
Hits: 214
<div>
<p>In June 2004, Gynuity convened a small group of international experts in the field of medical abortion and women’s health for a symposium held in Edinburgh, Scotland. Participants discussed current activities around novel abortifacient development and debated how best to balance resources between this research and efforts to improve existing medical abortion regimens. Participants included basic science researchers, social scientists, clinicians, and pharmaceutical industry experts. Much of the meeting focused on promising avenues of research and drug candidates in the areas of antiprogestins, other antihormones, prostaglandins and analogues, antifolates and antimetabolites, and angiogenesis inhibitor drugs (currently being developed as cancer therapies). More broadly, participants explored the qualities of an “ideal” abortifacient, as well as the social and political considerations involved in developing and promoting new therapies. Among the priority areas identified for future collaborative work were: 1) continuing to introduce medical abortion in countries where it is currently unavailable; 2) determining the lowest effective dose of misoprostol and developing single-dose regimens for mifepristone-misoprostol medical abortion; 3) establishing the minimum technology required for medical abortion; and 4) improving medical abortion for gestations >9 weeks.</p>
</div>
In June 2004, Gynuity convened a small group of international experts in the field of medical abortion and women’s health for a symposium held in Edinburgh, Scotland. Participants discussed current activities around novel abortifacient development and debated how best to balance resources between this research and efforts to improve existing medical abortion regimens. Participants included basic science researchers, social scientists, clinicians, and pharmaceutical industry experts. Much of the meeting focused on promising avenues of research and drug candidates in the areas of antiprogestins, other antihormones, prostaglandins and analogues, antifolates and antimetabolites, and angiogenesis inhibitor drugs (currently being developed as cancer therapies). More broadly, participants explored the qualities of an “ideal” abortifacient, as well as the social and political considerations involved in developing and promoting new therapies. Among the priority areas identified for future collaborative work were: 1) continuing to introduce medical abortion in countries where it is currently unavailable; 2) determining the lowest effective dose of misoprostol and developing single-dose regimens for mifepristone-misoprostol medical abortion; 3) establishing the minimum technology required for medical abortion; and 4) improving medical abortion for gestations >9 weeks.
Homepage: http://gynuity.org/resources/
Instructions for Use: Misoprostol for Treatment of Incomplete Abortion and Miscarriagehot!
11/30/2009
Hits: 212
Gynuity Health Projects and Reproductive Health Technologies Project convened an expert meeting looking at the use of misoprostol for incomplete abortion and miscarriage in 2004. Professionals with epidemiological, clinical and programmatic expertise reached consensus on the appropriate use of misoprostol based on the best current information. The results can be found in a brochure called “Instructions for Use – (IFU).” The information in this document may serve as a basis for the development of clinical practice guidelines and patient and provider education materials. The brochure was updated in June, 2008 based on new information and research developments.
Homepage: http://gynuity.org/resources/
This summary explores the complex question of whether using hormonal contraceptives could affect a woman’s risk of being infected with HIV or developing AIDS.
Homepage: http://gynuity.org/resources/
 |